Alyftrek 10/50/125 TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: vanzacaftor + tezacaftor + deutivacaftor
Pack: Alyftrek 10/50/125 tablet, 56, blister pack
Brand name
(ARTG)
: ALYFTREK 10/50/125 vanzacaftor (as calcium) 10 mg / tezacaftor 50 mg / deutivacaftor 125 mg film-coated tablet blister packConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
Alyftrek is indicated for the treatment of those who meet the diagnostic criteria for cystic fibrosis (CF) in people aged 6 years and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on clinical or in vitro evidence (see section 5.1 PHARMACODYNAMIC PROPERTIES, Table 4).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- Purple, capsule shaped tablet debossed with V10 on one side and plain on the other (15 mm x 7 mm)
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 56 film-coated tablets pack
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
